|
|
|
|
LEADER |
01948nam a2200373 u 4500 |
001 |
EB001865481 |
003 |
EBX01000000000000001029561 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
190504 r ||| eng |
245 |
0 |
0 |
|a CADTH Canadian drug expert committee recommendation: Latanoprost (Monoprost -- Laboratoires Thea)
|h Elektronische Ressource
|b indication : glaucoma and ocular hypertension
|
246 |
3 |
1 |
|a Drug reimbursement recommendation preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost)
|
246 |
3 |
1 |
|a Latanoprost (Monoprost -- Laboratoires Thea)
|
250 |
|
|
|a Version 1.0
|
260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2018, April 2018
|
300 |
|
|
|a 1 PDF file (7 pages)
|
653 |
|
|
|a Glaucoma / drug therapy
|
653 |
|
|
|a Canada
|
653 |
|
|
|a Ocular Hypertension / drug therapy
|
653 |
|
|
|a Latanoprost / therapeutic use
|
653 |
|
|
|a Cost-Benefit Analysis
|
653 |
|
|
|a Latanoprost / economics
|
653 |
|
|
|a Insurance, Health, Reimbursement / economics
|
653 |
|
|
|a Drug Costs
|
710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a CADTH common drug review
|
500 |
|
|
|a "Final."
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK532704
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
082 |
0 |
|
|a 330
|
520 |
|
|
|a The CADTH Canadian Drug Expert Committee (CDEC) recommends that preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost) be reimbursed for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, if the following condition is met: The drug plan cost of treatment with Monoprost should not exceed the drug plan cost of treatment with the least costly prostaglandin analogue (PGA)
|